Last updated: February 15, 2026
What Is NDC 00597-0295?
NDC 00597-0295 refers to Venclexta (venetoclax), marketed by AbbVie. It is an oral BCL-2 inhibitor approved for treating chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and various other hematologic malignancies.
Market Overview
Market Size and Demand Drivers
- The global hematological malignancy treatment market totaled approximately $10.8 billion in 2022, with a CAGR of 8% projected through 2028 (Source: Global Data).
- Venetoclax commands a significant share within this segment, driven by its approval for multiple indications and combination regimens.
- Key drivers include:
- Increasing prevalence of CLL/SLL, particularly among the elderly.
- Advancements in targeted therapy options.
- Adoption of venetoclax based regimens as standard of care.
Competitive Landscape
- Major competitors include:
- Ibrutinib (Imbruvica, AbbVie/Johnson & Johnson)
- Acalabrutinib (Calquence, AstraZeneca)
- Obinutuzumab-based regimens.
- Venetoclax's unique mechanism offers a competitive advantage, especially in patients with 17p deletion or relapsed/refractory disease.
Regulatory Status and Approvals
- FDA approved in 2016 for CLL with 17p deletion.
- Subsequent approvals expand its use to relapsed or refractory CLL/SLL, and combination therapies with obinutuzumab.
- EMA and other regulators have similar approvals.
Reimbursement Dynamics
- High-cost oncology treatments like venetoclax are generally reimbursed under specialty or oncology pathways.
- Payers are increasingly favoring targeted agents with proven survival benefits, supporting consistent reimbursement strategies.
- Patient access remains contingent on formulary decisions, regional policies, and negotiated discounts.
Price Trends and Projections
Current Pricing
- Wholesale Acquisition Cost (WAC): Approximately $13,500 per 30-day supply (Source: Red Book, 2023).
- Actual price paid (net price) often lower due to rebates, discounts, and patient assistance programs.
Market Penetration and Revenue Trends
- Estimated global sales reached $2.5 billion in 2022.
- Growth driven by expanding indications, including:
- Frontline CLL in combination with obinutuzumab.
- New formulations or delivery forms (potential future pipeline).
- Expected compounded annual growth rate (CAGR) of around 10% for the next five years, reaching approximately $4.1 billion globally by 2027.
Price Projection Factors
- Patent Status: Expiry of initial patents potentially by 2030; generic competition could drive prices down.
- Regulatory Approvals: New indications can bolster sales volume even if unit prices decline.
- Market Competition: Ibrutinib, acalabrutinib, and emerging therapies pose pricing pressure.
- Negotiated Discounts: Public and private payers can negotiate significant rebates; estimations suggest net prices could decrease by 15-20% over five years.
- Manufacturing and Supply Chain: Cost stabilization and scaling can influence pricing strategies.
Future Pricing and Revenue Outlook
| Year |
Estimated Global Sales |
Price per Unit (USD) |
Notes |
| 2023 |
$2.6 billion |
$13,500 per 30-day |
Baseline market size |
| 2024 |
$2.9 billion |
$13,200 (net estimate) |
Slight price decrease due to rebates |
| 2025 |
$3.2 billion |
$13,000 |
Expanded indications, market maturation |
| 2026 |
$3.6 billion |
$12,800 |
Entry of biosimilars, generic options |
| 2027 |
$4.1 billion |
$12,500 |
Competitive pressures increase |
Risks and Opportunities
Risks
- Patent expiration leading to generic competition.
- Pricing pressures from biosimilars and new entrants.
- Potential safety concerns influencing prescribing habits.
- Regulatory hurdles in expanding indications.
Opportunities
- Market expansion through new combination therapies.
- Geographic growth in emerging markets.
- Patient assistance programs mitigating access barriers.
Key Takeaways
- NDC 00597-0295 (Venclexta) is a leading targeted therapy in hematologic oncology with substantial current market share.
- The global market is projected to grow at around 10% CAGR through 2027, driven by expanded indications and geographic expansion.
- Current prices are approximately $13,500 per month in the U.S., with discounts likely reducing net prices by 15-20% over time.
- Patent expirations may usher in biosimilar competition around 2030, influencing future pricing.
- Revenue growth hinges on regulatory approvals, competitive dynamics, and payer strategies.
FAQs
1. When could generic versions of venetoclax become available?
Patent protections could expire around 2030, opening the market for biosimilars and generics, potentially reducing prices significantly.
2. How does venetoclax’s pricing compare to its competitors?
It is priced higher than many targeted oral cancer therapies, with a WAC of about $13,500 monthly, often offset by managed care discounts and rebates.
3. Which factors most influence venetoclax’s future sales?
Regulatory approvals for additional indications, market penetration in emerging territories, and biosimilar competition are primary drivers.
4. What are the key uncertainties impacting price projections?
Patent expiry timing, regulatory changes, competitive landscape shifts, and healthcare reimbursement policies.
5. Are there ongoing clinical trials that may boost further indications?
Yes, multiple trials are evaluating venetoclax combinations in AML, multiple myeloma, and other hematological malignancies, which could expand its market.
Sources
[1] Global Data. Hematology Oncology Market Report, 2022.
[2] Red Book, 2023 edition.
[3] FDA approval summaries.
[4] ABBVIE Annual Report, 2022.
